(NASDAQ: LAB) Standard Biotools's forecast annual revenue growth rate of 11.27% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 4.94%, and it is also forecast to beat the US market's average forecast revenue growth rate of 7.56%.
Standard Biotools's revenue in 2023 is $105,173,000.On average, 1 Wall Street analysts forecast LAB's revenue for 2023 to be $8,177,688,605, with the lowest LAB revenue forecast at $8,177,688,605, and the highest LAB revenue forecast at $8,177,688,605. On average, 1 Wall Street analysts forecast LAB's revenue for 2024 to be $9,543,283,207, with the lowest LAB revenue forecast at $9,543,283,207, and the highest LAB revenue forecast at $9,543,283,207.
In 2025, LAB is forecast to generate $11,623,433,124 in revenue, with the lowest revenue forecast at $11,623,433,124 and the highest revenue forecast at $11,623,433,124.